PMABPrevention and Management of Aggressive Behavior
PMABPurchasing Management Association of Boston
PMABPrototype Measurement and Analysis Branch
Copyright 1988-2018, All rights reserved.
References in periodicals archive ?
Bmab+Oxalipaltin+ Pmab 10 months, HR=1.27 CI; 95%, p=0.011) (OS for Bmab+Oxaliplatin 24.5 months vs.
ASPECCT: a randomized, multicenter, open-label, phase 3 study of panitumumab (pmab) vs cetuximab (cmab) for previously treated wild-type (WT) KRAS metastatic colorectal cancer (mCRC).
The clinical outcome of cetuximab and panitumumab administration as monotherapy and in combination with chemotherapy in mCRC patients Clinical Trial Treatment option Patients Kennecke H Mono PMab 178 (141 PMab, et al 2013 CMab Combo 37 CMab Combo) Price et al Mono CMab vs.
Fixation of deformation after ending loading and the recovery of beam (right part of the diagram) shows that the proportion of residual deformation for RBV is 16% of maximum deformation, for PMAB is 30%, and for BND is 43%, which confirms a more higher deformability of RBV at low temperatures at significantly lower residual deformations.
--reduction in cost of materials for the preparation of RBV compared to traditional PMAB due to refusal of plasticizer and significantly lower price of crumbs compared to the polymer;
"The PMAB decided the whole surveillance exercise was evidentially useless and effectively a total waste of public money.
Interim results from PACCE: irinotecan (Iri)/bevacizumab (bev) [+ or -] panitumumab (pmab) as first-line treatment (tx) for metastatic colorectal cancer (mCRC).